$ENVA

Fisher David sold $1.2M of ENVA

Fisher David (Executive Chairman) sold 7,180 shares of Enova International, Inc. (ENVA) at $160.37 ($1.15M total) on 2026-05-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fisher David
Published May 26, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ENVA
Neutral
medium confidence
Mentioned
$ENVA
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ENVANeutralMed
01

Why it matters

The disclosure provides information about insider liquidity and potential sentiment, but the presence of a pre-arranged 10b5-1 plan generally lowers the probability of a fundamental negative signal.

02

Market read

ENVA receives a Form 4 showing an executive chairman open-market sale (~$1.15M) under 10b5-1, which may cause limited short-term sentiment pressure.

03

What to watch

Traders may overreact to the headline dollar amount; the key nuance is the pre-arranged plan and the relatively small post-sale ownership change versus total shares.

Relevance 8/10Timing: Potential short-term sentiment/positioning impact as traders digest the Form 4 filing; no immediate catalyst beyond disclosure.

Background

The article is an SEC Form 4 insider transaction disclosure for Enova International, Inc. (ENVA).

Company-level read

Ticker impact

$ENVANeutralMedium confidence
Context

Enova executive chairman David Fisher sold $1.15M of ENVA shares via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low-to-moderate near-term downside/volatility risk around the filing date; longer-term impact likely limited.

Evidence & confidence

The filing specifies an open-market sale and a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal—this is company-specific insider activity without broader sector/regulatory signals.

None indicated; US-listed issuer disclosure only.

None indicated; no cross-border deal or operational update mentioned.

Counterpoint

The sale may reflect routine liquidity/portfolio rebalancing under a 10b5-1 plan rather than negative expectations.

Key entities

  • Enova International, Inc.

    Subject of the Form 4 insider sale by executive chairman David Fisher.

  • David Fisher

    Executive Chairman who sold 7,180 ENVA shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ENVAMed

Citizens Cuts Enova’s Price Target after its Bank Deal Falls Apart

Citizens analyst David Scharf cut Enova's (NYSE:ENVA) price target to $215 from $270 after it abandoned a bank acquisition deal. Enova cited unclear standards and slow approvals. The company reaffirmed its guidance for 25% revenue growth and 30% adjusted EPS growth in Q3. For the full year, it expects 20-25% revenue growth and 30-35% adjusted EPS growth. Enova reported strong Q2 results with 22% revenue growth and 33% adjusted EPS growth. The company plans to accelerate share repurchases.

$ENVAMed

Why Enova International Stock Was Plummeting This Week

Enova International (NYSE: ENVA) withdrew applications for banking licenses, causing its stock to drop nearly 20% week-to-date. The company cited unclear authorization processes and plans to focus on its existing business. Enova reaffirmed its 2026 revenue growth forecast of 20-25% and adjusted net income per share growth of 30-35%.